Drug intelligence / Profile preview

sorbolene cream

Development stage: Unknown
Lead developer: Trans-Tasman Radiation Oncology Group
Modality: Small Molecules
Administration: Topical

Overview

Sorbolene cream is a topical emollient and humectant formulation typically containing 10% glycerine along with paraffin and mineral oils. It is used to maintain skin hydration and barrier function. In clinical oncology, specifically within the Trans Tasman Radiation Oncology Group (TROG) 04.01 trial, it was utilized as the standard-of-care control for the prophylactic management of radiation dermatitis in breast cancer patients receiving post-mastectomy radiotherapy. The cream works by attracting moisture to the stratum corneum and providing an occlusive layer to prevent transepidermal water loss, thereby mitigating the severity of radiation-induced skin reactions.

Brand names: Sorbolene
Other names: 10% glycerine cream10% glycerin cream

Beyond the preview

Go deeper on sorbolene cream.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on sorbolene cream.

Explore the full profile